TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3051324
Drug: 1-21 fragment
Normalized name: PALMITOYL FRAGMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-21 fragment of pancreatic glucagon (G 1-21)
Study: 28357975
Drug: MicroExpression Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: MicroExpression Training Tool (METT), twice weekly for 4 weeks
Study: 23850170
Drug: Treatment selection
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment selection based on biomarkers
Study: 19567516
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg oral vitamin D(3) (n = 8)
Study: 19567516
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg oral vitamin D(2) (n = 9)
Study: 15365313
Drug: Energy drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy drink (3.57 ml/kg Red Bull)
Study: 10931079
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (1000 mg) + oral levonorgestrel (250 microg daily)
Study: 10931079
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (1000 mg) + oral placebo
Study: 7876402
Drug: Nabumetone (NAB)
Normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nabumetone (NAB) 1000 mg daily
Study: 7876402
Drug: Indomethacin (IND)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (IND) 50 mg every 12 hours
Study: 7876402
Drug: Sulindac (SUL)
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac (SUL) 200 mg every 12 hours
Study: 31770016
Drug: Scutellaria baicalensis
Normalized name: SCUTELLARIA BAICALENSIS
DrugBank: Scutellaria baicalensis root (DB14364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scutellaria baicalensis (SB) 3.52 g/day
Study: 23819242
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection with small dose of fentanyl-droperido mixed liquor
Study: 23819242
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection with fentanyl-droperido mixed liquor
Study: 23819242
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 0.9% NaCl
Study: 21059094
Drug: Linagliptin 1
Normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 1 mg
Study: 21059094
Drug: Glimepiride (1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1-3 mg)
Study: 16996844
Drug: Enoxaparin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1.5 mg/kg daily for 3 months)
Study: 16996844
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (angiotensin-converting enzyme inhibitors, beta-blockers, diuretics)
Study: 12000508
Drug: Clotrimazole 1%
Normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole 1% cream, once daily
Study: 12000508
Drug: Ketoconazole 2%
Normalized name: KETOCONAZOLE 2% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 2% cream, twice daily
Study: 9509380
Drug: Yohimbine (5.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (5.4 mg orally, 3 times daily, beginning at menses)
Study: 2195890
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of netilmicin (2 g ceftriaxone also administered)
Study: 2195890
Drug: Conventional multiple-daily-dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional multiple-daily-dosing regimen of netilmicin (2 g ceftriaxone also administered)
Study: 8514653
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of netilmicin
Study: 2195890
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses of netilmicin
Study: 2195890
Drug: Once-daily doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily doses of netilmicin
Study: 2195890
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of netilmicin plus ceftriaxone
Study: 3494725
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 g single dose)
Study: 3494725
Drug: Metronidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (2 g single dose)
Study: 6804724
Drug: EPSDT program
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPSDT program (early and periodic screening, diagnosis and treatment)
Study: 21135795
Drug: Standardized local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized local treatment combined with compression therapy
Study: 17917828
Drug: Adjuvant 5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant 5‐fluorouracil (5FU) based chemotherapy
Study: 17917828
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy in rectal cancer patients
Study: 15501929
Drug: Urine Na+
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine Na+ and K+ excretion
Study: 15501929
Drug: Antidiuretic hormone
Normalized name: Antidiuretic hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiuretic hormone levels
Study: 11899188
Drug: L-arginine-enriched solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine-enriched solution (7.5 g/500 mL)
Study: 11899188
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood cardioplegic solution (Control)
Study: 7621490
Drug: Topical applications
Normalized name: honey based topical applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical applications of amine fluoride solution (1%) - Group A (positive control)
Study: 7621490
Drug: Topical applications
Normalized name: honey based topical applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical applications of amine fluoride solution (0.5% F) - Group B
Study: 7621490
Drug: Topical applications
Normalized name: honey based topical applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical applications of amine fluoride solution (0.25% F) - Group C
Study: 7196807
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m2
Study: 2689396
Drug: Cisplatin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (all doses) with hyperthermia and radiation
Study: 23458673
Drug: Anti-cocaine vaccine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-cocaine vaccine
Study: 21284801
Drug: TB-402 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB-402 0.3 mg kg(‐1)
Study: 21284801
Drug: TB-402 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB-402 0.6 mg kg(‐1)
Study: 21284801
Drug: TB-402 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB-402 1.2 mg kg(‐1)
Study: 22215944
Drug: Spray
Normalized name: Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray
Study: 17341515
Drug: Self-administered electronic
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered electronic questionnaire
Study: 17341515
Drug: Self-administered paper-and-pencil
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered paper-and-pencil questionnaire
Study: 17341515
Drug: Orally-administered interview
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally-administered interview questionnaire
Study: 12133040
Drug: eletriptan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: eletriptan 80 mg
Study: 9794981
Drug: Ibuprofen syrup
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen syrup (20 mg/mL, 0.25 mL per kg per dose, administered every 6 hours during fever)
Study: 9794981
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching syrup, administered every 6 hours during fever)
Study: 509345
Drug: Physostigmine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine administered immediately upon termination of anaesthesia
Study: 509345
Drug: Physostigmine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine administered 30 minutes after the last dose of ketamine
Study: 30009735
Drug: Qingfeihuayutongfu prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingfeihuayutongfu prescription (200 mL through nasal feeding, one dose per day for 7 days)
Study: 30009735
Drug: Qingfeihuayutongfu prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingfeihuayutongfu prescription
Study: 22626799
Drug: Transhiatal esophagectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transhiatal esophagectomy after chemotherapy
Study: 22626799
Drug: Transhiatal esophagectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transhiatal esophagectomy without chemotherapy
Study: 22626799
Drug: Transhiatal esophagectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transhiatal esophagectomy with chemotherapy
Study: 11738765
Drug: Anthrax vaccine
Normalized name: ANTHRAX VACCINE
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthrax vaccine (AVA)
Study: 9430010
Drug: Erythromycin (EM)
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin (EM) 250 mg intravenously
Study: 2896401
Drug: Standardized hemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized hemodilution treatment (venesection and dextran 40 administration)
Study: 2896401
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hemodilution treatment)
Study: 30098962
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion furosemide
Study: 12517329
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine
Study: 30098962
Drug: No low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No low-dose dopamine
Study: 26194361
Drug: Carboplatin/taxane chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/taxane chemotherapy
Study: 20671038
Drug: β‐alanine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐alanine (5 g/day)
Study: 10931579
Drug: MnDPDP injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: MnDPDP injection (5 micromol/kg)
Study: 8154130
Drug: Heparin-induced extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-induced extracorporeal LDL precipitation (HELP)
Study: 27056964
Drug: Transcatheter patent
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter patent foramen ovale closure plus antiplatelet therapy
Study: 24013574
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) alone at 60 mg on day 1
Study: 24013574
Drug: Panobinostat at
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat at 20 mg alone on days 3 and 5
Study: 24013574
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) and panobinostat co-administered on day 8
Study: 8814419
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ) 150 mg per day for 6 months
Study: 1306815
Drug: Nitrendipine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (active treatment group, 45 patients)
Study: 2867800
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg thiotepa instillation at the time of primary treatment
Study: 2867800
Drug: Instillations of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillations of thiotepa at 3‐monthly intervals for a year
Study: 19752319
Drug: Dronedarone 400
Normalized name: dronedarone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone 400 mg BID
Study: 25134972
Drug: Propafenone 150
Normalized name: propafenone 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 150 mg TID
Study: 1385929
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg (5 mg for patients ≤30 kg)
Study: 1385929
Drug: Astemizole 2
Normalized name: astemizole 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 2 mg/10 kg body weight
Study: 6502473
Drug: Antacid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid regimen administered for three full days
Study: 6502473
Drug: Theophylline therapy
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline therapy with antacids
Study: 6502473
Drug: Control (theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (theophylline therapy without antacids)
Study: 30291402
Drug: Very-low-nicotine-content cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Very-low-nicotine-content cigarettes (VLNCCs; 1 mg nicotine/g tobacco)
Study: 30291402
Drug: Normal-nicotine-content cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal-nicotine-content cigarettes (NNCCs; 16 mg/g)
Study: 24214217
Drug: sipoglitazar (8,
Approvals — FDA: no, EMA: no, PMDA: no
Description: sipoglitazar (8, 16, 32, or 64 mg once daily; 16 or 32 mg twice daily)
Study: 24214217
Drug: rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (8 mg once daily)
Study: 10669372
Drug: Meningococcal C
Normalized name: meningococcal conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal C conjugate (MCC) vaccine
Study: 11865832
Drug: Pentoxifylline (PXF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PXF) 2400 mg (four 600‐mg tablets daily) for 10 days
Study: 1700873
Drug: Colloid (hydroxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid (hydroxy ethyl starch) and electrolyte solution (group COL)
Study: 31873746
Drug: Cabotegravir LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir LA 400 mg + Rilpivirine LA 600 mg IM every 4 weeks
Study: 31873746
Drug: Cabotegravir LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir LA 600 mg + Rilpivirine LA 900 mg IM every 8 weeks
Study: 22008041
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection treatment
Study: 14999237
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of the International Prostate Symptom Score (IPSS) questionnaire.
Study: 14999237
Drug: Physician administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician administration of the International Prostate Symptom Score (IPSS) questionnaire.
Study: 11260005
Drug: Calcitriol 3
Normalized name: CALCITRIOL 3MCG/GM OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 3 microg g-1 ointment plus UVB phototherapy
Study: 9554807
Drug: losartan, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan, 50 mg for 14 days
Study: 7748145
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g one hour before breakfast and dinner)
Study: 3058398
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate ointment (0.1 percent), applied once daily
Study: 3058398
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate cream (0.1 percent), applied once daily
Study: 3058398
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate ointment and cream (0.1 percent)
Study: 3058398
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide ointment (0.025 percent), applied three times daily
Study: 3058398
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide ointment (0.1 percent), applied twice daily
Study: 3058398
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide cream (0.025 percent), applied three times daily
Study: 3058398
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide cream (0.1 percent), applied twice daily
Study: 31680378
Drug: Eshnan (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eshnan (500 mg, three tablets taken orally after each meal for 2 months)
Study: 31680378
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three tablets taken orally after each meal for 2 months)
Study: 29551324
Drug: Motivational outreach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational outreach call, multisession telephone counseling, and assistance with obtaining nicotine replacement therapy
Study: 29551324
Drug: Usual Veterans
Normalized name: benzalkonium chloride Topical Foam [Veteran Shield 24]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Veterans Administration smoking services
Study: 23255783
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of immunoglobulin A antibodies to Epstein‐Barr virus capsid antigen and nuclear antigen‐1 by enzyme‐linked immunosorbent assay and indirect mirror examination in the nasopharynx and/or lymphatic palpation (IMLP)
Study: 1606996
Drug: Oxazepam 10
Normalized name: oxazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 10 mg
Study: 9065993
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) (n = 28)
Study: 9065993
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) (n = 32)
Study: 30285811
Drug: Single use
Normalized name: CLIN Single Use Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single use negative pressure wound therapy (sNPWT)
Study: 24212478
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg 0.5% isobaric levobupivacaine
Study: 24212478
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg 0.5% isobaric bupivacaine
Study: 15837439
Drug: Subjects lacking
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects lacking strong preferences for treatment
Study: 15837439
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with strong preferences for treatment
Study: 1759004
Drug: Salbutamol aerosol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol aerosol 400 micrograms before and 200 micrograms 2-hourly after challenge
Study: 1759004
Drug: Oral terfenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terfenadine 120 mg 2 h before and 10 h after challenge
Study: 1759004
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication or antigen challenge
Study: 30879831
Drug: XEN® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN® Gel Stent as a stand-alone procedure
Study: 30879831
Drug: XEN® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN® Gel Stent in combined surgery
Study: 30683533
Drug: XEN® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN® Gel Stent (both procedures)
Study: 28374714
Drug: Collost (medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collost (medical device) in addition to standard therapy
Study: 23705925
Drug: Cinacalcet +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet + oral vitamin D (n = 33)
Study: 23705925
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D alone (control group, n = 33)
Study: 2488104
Drug: Controlled-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release metoprolol (CR) 100 mg
Study: 2488104
Drug: Controlled-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release metoprolol (CR) 200 mg
Study: 2488104
Drug: Metoprolol Durules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol Durules 200 mg
Study: 2488104
Drug: Metoprolol plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol plain tablet 100 mg
Study: 13418
Drug: TRH administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH administered to 6 patients with endogenous depressions
Study: 13418
Drug: MIF-1 60
Normalized name: Immunoglobulin g1-kappa, anti-(homo sapiens mif (macrophage migration inhibitory factor, glycosylation-inhibiting factor, glif, gif)), homo sapiens monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIF-1 60 mg per day for 6 days
Study: 13418
Drug: MIF-1 150
Normalized name: Immunoglobulin g1-kappa, anti-(homo sapiens mif (macrophage migration inhibitory factor, glycosylation-inhibiting factor, glif, gif)), homo sapiens monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIF-1 150 mg per day